Skip to main content
. 2009 Sep 4;4(9):e6893. doi: 10.1371/journal.pone.0006893

Figure 8. Quantification of epithelial ECS immunoreactivity depending on the treatment received.

Figure 8

As a relevant finding, treatment is associated with changes in the expression of cannabinoid receptors and EC-production and -degradation enzymes, suggesting that these proteins can be considered as biomarkers of active disease/response to treatment. Histograms represent the mean±SEM. U Mann Witney and Wilcoxon tests: *P<0.05 and **P<0.01 versus control group; #P<0.05 versus acute group. N = 3, 15 and 6 for 5-ASA, 5-ASA+corticosteroids and 5-ASA+corticosteroids+immunomodulators respectively.